Search

Federal Circuit Upholds Anti-CGRP Antibody Method Claims Against Eli Lilly

The Federal Circuit reversed a district court's judgment as a matter of law in Teva Pharmaceuticals International GmbH v. Eli Lilly & Co., No. 2024-1094, upholding method-of-treatment patents directed to using anti-CGRP antagonist antibodies to treat headaches. The court held that written description and enablement requirements under 35 U.S.C. § 112 may be satisfied for method claims even when the claims recite a broad genus of antibodies defined by binding target without amino acid sequences. The decision distinguishes method-of-treatment claims from composition claims, finding the invention is the use of antibodies to treat headache rather than the antibodies themselves.

CHMP Meeting Agenda Annex Lists 22 Products Under Review

EMA published the annex to the CHMP meeting agenda for 23-26 March 2026 (EMA/CHMP/49808/2026), covering 22 pharmaceutical products across annual reassessments, PSUR procedures, renewals, and variation type IB updates. Products under review include Lojuxta, Raxone, Defitelio, CARVYKTI, Fycompa, Tecvayli, Qdenga, RINVOQ, Kapruvia, Voxzogo, ALTUVOCT, Ezmekly, Lytgobi, Rozlytrek, Duvyzat, Aucatzyl, Fingolimod Mylan, Cometriq, Bylvay KAYFANDA, Imatinib Teva, Ranivisio Epruvy, Xarelto, Forxiga/Xigduo/Qtern/Edistride/Ebymect. This is a procedural working document; it does not create compliance obligations.